The goal of successful anti-tumoural immunity is the development of long-term protective immunity to prevent relapse. Infiltration of tumours with CD8 þ T cells with a resident memory (Trm) phenotype correlates with improved survival. However, the interplay of circulating CD8 þ T cells and Trm cells remains poorly explored in tumour immunity. Using different vaccination strategies that fine-tune the generation of Trm cells or circulating memory T cells, here we show that, while both subsets are sufficient for anti-tumour immunity, the presence of Trm cells improves anti-tumour efficacy. Transferred central memory T cells (Tcm) generate Trm cells following viral infection or tumour challenge. Anti-PD-1 treatment promotes infiltration of transferred Tcm cells within tumours, improving anti-tumour immunity. Moreover, Batf3-dependent dendritic cells are essential for reactivation of circulating memory anti-tumour response. Our findings show the plasticity, collaboration and requirements for reactivation of memory CD8 þ T cells subsets needed for optimal tumour vaccination and immunotherapy.
G eneration of optimal cancer immunotherapy involves induction of effective memory against the primary tumour able to prevent relapse metastases and recurrence. Circulating memory cells patrol the blood and include central memory T (Tcm) cells that retain the capacity to enter lymph nodes (LNs). Conversely, tissue-resident memory T (Trm) cells are confined to parenchymal non-lymphoid tissues [1] [2] [3] [4] [5] [6] [7] . Trm are characterized by stable surface expression of CD69 and an enhanced effector ability that functionally provides a tissue-wide alert state against local reinfection [6] [7] [8] [9] [10] [11] .
In mice, cutaneous infection with recombinant vaccinia virus (rVACV) generates circulating memory CD8 þ T cells and skin Trm cells, whereas i.p. infection does not generate skin Trm cells 12 . Infected parabiotic mice with skin Trm cells are more resistant to a rechallenge dermal infection than their circulation-sharing partners lacking Trm cells 12 . Optimal generation of Trm cells requires Batf3-dependent dendritic cells (DCs) during priming following VACV infection 13 . Batf3 À / À mice show impaired immunity against syngeneic fibrosarcomas with marked intrinsic immunogenicity 14 . Tumour infiltration by CD103 þ Batf3-dependent DCs correlates with tumour regression 15 and favours T-cell infiltration in mouse models of melanoma 16 . CD103 þ DCs mediate antigen capture within the tumour and cross-prime tumour-specific CD8 þ T cells, whose therapeutic effects can be amplified by immunostimulatory antibodies 17, 18 .
The interplay between circulating CD8 þ T cells and Trm cells in anti-tumour immunity is largely unexplored. Previous studies in human cancer show that the infiltration of tumours by T cells with a Trm cell-like phenotype correlates with improved overall survival in early stage non-small-cell lung carcinoma, pulmonary squamous cell carcinoma and high-grade serous epithelial ovarian cancer [19] [20] [21] . In addition, recent results suggest that vaccination routes that promote generation of Trm cells could be more effective for anti-tumour response 22, 23 . These findings prompted us to analyse the relative contribution and plasticity of circulating memory CD8 þ T cells and Trm cells in a model of anti-tumour vaccination.
In the present study, we demonstrate that circulating CD8 þ T cells and Trm cells cooperate in anti-tumour immunity. The circulating memory compartment retains enough degree of plasticity to become cells with a Trm phenotype within the grafted tumour and reside in the skin after tumour elimination. Immunotherapy with anti-PD-1 synergizes with transfer of tumour-specific Tcm cells, increasing CD8 þ T-cell infiltration of tumours. In addition, Batf3-dependent DCs are crucial for reactivation of circulating CD8 þ T-cell memory, inducing antitumour immunity. Knowledge on the generation of optimal memory against tumour antigens is essential for improved cancer immunotherapy.
Results

Trm and circulating memory promote anti-tumour response.
To investigate the potential interplay between circulating memory and Trm CD8 þ T cells in anti-tumour immunity we first infected mice with rVACV-OVA by different routes and measured circulating and resident memory at 30 d.p.i. Frequencies of endogenous OVA-specific circulating memory T cells were similar regardless the infection route ( Fig. 1a and Supplementary Fig. 1a ). Whereas intraperitoneal (i.p.) infection with rVACV-OVA was inefficient for the generation of Trm cells in the skin or the lung, skin scarification (s.s.) in the tail promoted Trm cells in the infection site and in a distant cutaneous site, and intranasal (i.n.) infection induced Trm cells in the lung (Fig. 1b-d and Supplementary Fig. 1b-d) .
To address the contribution of circulating and Trm CD8 þ T cells to control tumour growth, mice were infected with rVACV-OVA by s.s. or i.p. and, after generation of resident and/or circulating memory from the endogenous repertoire 30 days later 12 , were inoculated intradermally (i.d.) with B16-OVA cells (Fig. 2a) . We used the S1P antagonist FTY720 to block egress of T cells from LN into blood 12 and, in this way, limit the contribution of circulating memory T cells to the recall response. FTY720 administration at 30 days following rVACV-OVA i.p. or s.s. infection significantly reduced the presence of blood OVAspecific T circulating memory to the numbers observed in naive mice (Fig. 2b,c) . Circulating memory T cells generated by i.p. vaccination with rVACV-OVA were sufficient to delay B16-OVA melanoma growth and this effect was significantly impaired by administration of FTY720 just before tumour inoculation and during tumour growth (Fig. 2d) , demonstrating that circulating memory T cells protect against tumour development. However, following s.s. with rVACV-OVA, FTY720 treatment failed to reverse the enhanced tumour rejection (Fig. 2e) , suggesting that Trm cells generated by this route are also sufficient for effective anti-tumour immunity. Thus, both circulating memory and Trm CD8 þ T cells are sufficient for anti-tumour immunity, resulting in delayed growth of B16-OVA-derived melanoma.
Trm improve anti-tumour immunity. To study the potential contribution of Trm cells to control melanoma growth in the presence of circulating memory T cells, we employed a parabiosis strategy with mice sharing circulating memory, but with only one of the parabionts bearing Trm (Fig. 3a) . Accordingly, mice were infected by s.s. with rVACV-OVA 30 days before surgical parabiosis with naive mice and, after allowing a further 30-day period to equilibrate circulating memory T cells (Fig. 3b) , parabiont mice were separated, allowed to recover and injected i.d. with B16-OVA cells. When compared with tumour-challenged naive mice, both infected or uninfected parabionts were significantly protected (Fig. 3c,d ). However, when compared with uninfected partners that shared circulating memory T cells, detectable tumour onset was delayed in infected parabionts containing Trm cells (Fig. 3c) . The delayed tumour incidence in infected parabionts containing Trm cells also resulted in significantly reduced tumour growth (Fig. 3d) . Thus, the presence of Trm cells together with circulating memory T cells improves anti-tumour immunity in contrast to an environment containing only circulating memory CD8 þ T cells.
Plasticity of Tcm to become Trm upon viral challenge. Next, we investigated the potential plasticity of circulating memory CD8 þ T cells to produce Trm cells. Naive OT-I (CD44 lo CD62L hi ) cells are plastic and can become both circulating and skin-resident memory T cells upon transfer to mice subsequently infected in the skin with rVACV-OVA to favour Trm cell differentiation 13, 24 . Mice transferred with naive OT-I cells and challenged i.d. with rVACV-OVA were used as source for OT-I Tcm cells 30 d.p.i. (Fig. 4a) . Using naive OT-I cells as a positive control, we tested whether transfer of OT-I Tcm cells (CD44 hi CD62L hi ) could generate Trm cells in the skin 30 days or 60 days after infection i.d. with rVACV-OVA along with Tcm or naive OT-I transfer (Fig. 4a) . Notably, Tcm cells generated Trm cells, defined as OT-I T cells in the skin 30 days or 60 days after viral infection and OT-I Tcm cell transfer, albeit with a lower efficiency than naive T cells (Fig. 4b,c) . The majority of skin OT-I Trm cells derived from transferred OT-I Tcm cells showed stable CD69 expression with 50% of them co-expressing CD103 (Fig. 4d) , which is consistent with previous results 12, 13 . To functionally demonstrate that OT-I Trm cells derived from Tcm cells following viral infection were truly resident, we tested their ability to migrate via blood or lymph once they were established (Fig. 4e ). Mice were transferred with OT-I Tcm cells one day before infection with rVACV-OVA. After 30 d.p.i., surgical parabiosis of infected and naive mice was performed, leaving 30 days to equilibrate circulating memory compartments. Infected and non-infected parabionts were subsequently analysed for the presence of OT-I circulating memory cells in the spleen (Fig. 4f) and Trm cells in the ear (Fig. 4g,h ). Only the infected parabionts exhibited OT-I Trm cells in the ear skin, functionally demonstrating that Trm derived from Tcm cells are unable to migrate via blood or lymph.
Tcm give rise to Trm cells upon tumour inoculation. To analyse whether Tcm cell plasticity to generate Trm cells is also found in the tumour setting, OT-I Tcm cells were transferred to recipient mice that were subsequently inoculated i.d. with B16-OVA cells or injected subcutaneously (s.c.) with MC38-OVA (Fig. 5a ). Following 20 days of B16-OVA tumour development, OT-I cells with a Trm cell-like phenotype, with most OT-I T cells expressing CD69 and 50% of them co-expressing CD103, were found in the tumour mass ( Fig. 5b-d ). In addition, since Tcm transfer resulted in elimination of MC38-OVA (Fig. 5e) , we analysed the presence of Trm cells in the skin that was in the proximity of the rejected tumour. Skin OT-I Trm cells expressing CD69 and CD103 were found 20 days and 45 days after tumour inoculation ( Anti-tumour memory response is impaired in Batf3 À / À mice. The generation of Trm cells but not circulating memory T cells by VACV infection is dependent on Batf3-dependent cross-presenting DCs 13 . Consistent with this, we found that generation of endogenous repertoire OVA-specific Trm cells induced by s.s. with rVACV-OVA (Fig. 7a,b ), but not circulating memory CD8 þ T cells (Fig. 7c) , was impaired in Batf3 À / À mice. We therefore hypothesized that impaired Trm cell generation in Batf3 À / À mice could lead to a defective anti-tumour response. We found that Batf3 significantly contributed to anti-tumour immunity following s.s. of mice with rVACV-OVA (Fig. 7d ). Batf3 was also required for effective anti-tumour response after i.n. infection with rVACV-OVA and subsequent intravenous (i.v.) challenge with B16-OVA cells (Fig. 7e) . These results supported our initial hypothesis, as both s.s. and i.n. routes of infection generate Trm cells. However, Batf3 was also required to control tumour growth following routes that do not produce Trm, such as i.p. infection with rVACV-OVA and i.d. challenge with B16-OVA cells (Fig. 7f) rVACV-OVA and i.v. challenge with B16-OVA cells (Fig. 7g) . Collectively these results demonstrate that Batf3-dependent DCs contribute to the anti-tumour CD8 þ T-cell memory response independently of their role in the generation of Trm cells. CD8 þ T cells raised in Batf3 À / À mice were not functional for anti-tumour immunity, we i.d. infected WT and Batf3 À / À mice with rVACV-OVA following OT-I cells transfer, and then transferred purified OT-I Tcm cells to WT recipients (Fig. 8a) . Following i.d. challenge with B16-OVA cells, Tcm cell transfer was equally effective in delaying tumour growth irrespective of whether they were generated in WT or in Batf3 À / À mice (Fig. 8b) . We thus hypothesized that recipient Batf3-deficient DCs would mediate inefficient reactivation of the transferred Tcm against the tumour. To test this, we generated OT-I Tcm cells in WT (Fig. 8c) or Batf3 À / À (Fig. 8d ) donor mice and transferred them to WT or Batf3 À / À recipient mice that were i.d. challenged with B16-OVA cells. Independently of the origin of Tcm cells, transfer to Batf3 À / À recipients resulted in impaired anti-tumour immunity with respect to transfer to WT recipients (Fig. 8c,d ).
These data demonstrate that Batf3-dependent DCs are requisite for reactivation of Tcm cells promoting anti-tumour immunity.
Discussion
Optimal tumour immunotherapy should generate a potent memory CD8 þ T cell to prevent local relapse and metastasis. Memory CD8 þ T cell can be either circulating or resident in the tissues (Trm) exhibiting different priming and differentiation requirements 3, 5, 6, 13 . Circulating memory and Trm cells also show different effector behaviour 6 , but their interplay in tumour immunity remains poorly characterized. In the present study, we demonstrate that circulating memory CD8 þ T cells and Trm cells cooperate in anti-tumour immunity, with the circulating memory compartment retaining enough degree of plasticity to become resident memory cells within the grafted tumour or in the proximal skin following tumour elimination. Notably, anti-PD-1 therapy synergizes to improve anti-tumour immunity following Tcm transfer. Moreover, Batf3-dependent DCs are crucial for reactivation of circulating CD8 þ T-cell memory for anti-tumour immunity.
Trm cells are generated following most viral infections affecting the skin or mucosae 6 and are broadly distributed in tissues 7 . Trm cells respond faster to stimulation than circulating memory T cells, and they are equipped with a more potent effector response than their circulating counterparts 11 . Moreover, Trm cells provide superior protection upon viral reinfection in skin or mucosae and are sufficient to control viral reinfection in the presence of FTY720, which prevents the contribution of circulating memory T cells 12 . Our experiments using FTY720 showed that Trm were potentially sufficient for anti-tumour immunity. However, we also found that circulating memory CD8 þ T cells mediate effective anti-tumour immunity, in agreement with previous results 25 . Using a parabiosis strategy, we demonstrate that melanoma tumour growth is slower in mice containing both Trm and circulating memory T cells than in parabionts containing only circulating memory T cells, thus supporting the notion that resident and circulating memory subsets cooperate for enhanced anti-tumour immunity. The differential kinetics in the effector response of resident and circulating memory subsets has been shown in other experimental settings, such as cutaneous hypersensitivity, where Trm mediate rapid responses, whereas circulating memory T cells mediate delayed hypersensitivity 26 . Conceivably upon viral rechallenge, Trm cells trigger a local alarm state that promotes immunity 9, 10, 27 . Our data showing delayed tumour incidence and growth in the presence of Trm suggest that these cells could be particularly efficient in preventing metastasis.
The plasticity of Tcm cells to generate Trm cells had not been previously addressed. Tcm and Trm cells have a clonal origin, sharing TCR repertoires 26 , but display distinct priming requirements in the LN 13 . Optimal generation of Trm cells following rVACV infection requires unique priming signals provided by Batf3-dependent DCs that favour T-bet expression and LN retention 13 . Subsequently, Trm cells migrate to the tissue, where the local microenvironment conditions Trm cells differentiation 6, 7, 28 . Tcm cells exhibit more stem-like and proliferative capacities after re-exposure to antigen, whereas Trm cells have a higher effector capacity and trigger a local alarm state [8] [9] [10] tumour rejection. The capacity to generate Trm cells subsets upon reinfection or tumour challenge supports at least partial stemness properties of Tcm cells, which do not convert into Trm under steady-state conditions in the absence of viral infection or tumour implantation 12 .
DCs are essential for anti-tumour immunity by adoptively transferred T cells, since transfer of preactivated OT-I cells to DC-depleted mice leads to impaired protection against tumour cells expressing OVA 15 . In the tumour context, recent studies show that Batf3-dependent CD103 þ DCs play a crucial role in anti-tumour immunity [15] [16] [17] [18] 29 . Batf3-dependent DCs crosspresent tumour antigens and generate a baseline anti-tumour response that can be potentiated by immunostimulating antibodies in synergy with expansion and activation of this DC subset using Flt3L and poly I:C (refs 17,18). Batf3-dependent DCs are also major producers of IL-12, not only in infectious settings [30] [31] [32] , but also in the context of tumours, where IL-12 contributes to CD8 effector function 29 . In addition, Batf3-dependent DCs are required for the recruitment of naive CD3 þ T cells to the tumour site 16 in a spontaneous melanoma model. Here we show that Batf3-dependent DCs are needed for effective reactivation of Tcm cells to promote anti-tumour immunity, which further supports the crucial role of this DC subset in tumour immunology and immunotherapy, not only for the primary response, but also for the memory response. Our data in the tumour context concur with previous data on the role of Batf3-dependent DCs in reactivation of memory CD8 þ T-cell recall response upon infection with Listeria monocytogenes, vesicular stomatitis virus or vaccinia virus 33 . We cannot rule out, however, that the role of Batf3-dependent DCs in generation of Trm 13 is also important in the context of tumours or that additional DC subsets may activate Trm 34 .
Our results suggest that CD8-mediated anti-tumour immunity arises from the interplay between resident and circulating memory CD8 þ T cells. Circulating memory cells show enough plasticity to generate Trm cells upon tumour challenge and they both express PD-1, similarly to CD103 þ T cells infiltrating highgrade serous epithelial ovarian cancer 35 . Thus, anti-PD-1 therapy synergizes with transfer of Tcm cells for improved anti-tumour immunity, increasing the infiltration of Trm-like cells expressing PD-1 within the tumour. These results concur with previous data showing that anti-PD-1 expands intratumoural memory T cells in patients 36 . Within samples of melanoma, immune checkpoints are particularly enriched within T cells with phenotype and genomic features of Trm cells, suggesting that the Trm subset of TILs may be the major target of immune checkpoint blockade 37 . Moreover, other immunostimulatory antibodies, such as anti-CD137, could also enhance the resident memory response 38 . In conclusion, our results support the notion that anti-tumour vaccination strategies should aim at the generation of both circulating and resident memory CD8 þ T-cell subsets 22, 23, 39 , which could synergize with checkpoint antibody therapy for improved cancer immunotherapy.
Methods
Mice. Mice were bred and housed at the CNIC animal facility in specific pathogenfree conditions. Batf3 À / À mice on the C57BL/6 background were kindly provided by Dr K.M. Murphy (Washington University, St Louis, MO, USA) 14 . OT-I transgenic mice (C57BL/6-Tg (TcraTcrb)1100Mjb/J) were mated with B6-SJL (Ptprca Pepcb/BoyJ) mice expressing the CD45.1 allele, both from The Jackson Laboratory (Bar Harbor, ME, USA). We used 7-to 10-week-old animals (males or females) for all experiments. Experiments were repeated 2-3 times to reach statistical significance. No blinding or randomization strategy was used and no animal was excluded from analysis. For FACS analysis mice were killed at day 7 after Tcm transference.
Parabiosis. Parabiosis was performed as described 12 . For tumour inoculation, wild-type (WT) mice were infected with rVACV-OVA (10 6 Flow cytometry. Allophycocyanin-labelled dextramers specific for OVA H-2Kb (257-SIINFEKL-264) were purchased from Immudex (Copenhagen, Denmark). Samples for flow cytometry were stained with the appropriate antibody cocktails in ice-cold PBS supplemented with 2 mM EDTA and 1% FBS. Anti-mouse CD45 (clone 30F11), CD8a (clone 53-6.7), CD103 (clone 2E7), CD44 (clone IM7), CD45.1 (clone A20) and CD45.2 (clone 104) antibodies were obtained from eBioscience. Anti-mouse CD62L (clone MEL-14) and CD69 (clone H1.2F3) antibodies were obtained from BD Biosciences. Anti-mouse CD279 (PD-1, clone 29F.1A12) was obtained from Biolegend. Events were acquired using an LSRFortessa SORP (Becton Dickinson) flow cytometer or Spectral Cell Analyzer SP6800 (Sony) and data were analysed using FlowJo V10 software (Tree Star).
Statistical analysis. Statistical analysis was performed using Prism v6 (GraphPad Software Inc., La Jolla, CA, USA). We estimated a priori that minimal informative differences are 1 SD, and estimated sample sizes using software 'Gpower 1.3', taking into account the following considerations. (a) The differences to be detected, 1 SD comparing each group of mice. Ratio (effect size) differs to detect/SD ¼ 1. (b) Taking into account the above data, the number of animals in total for a contrast t-test of mean differences between two independent groups with two tails is 17. Power ¼ 0.8 and significance level ¼ 0.05. Variance equality among groups was determined using F-test. Statistical significance for comparison between two groups of samples showing a normal distribution (Shapiro-Wilk test for normality) was determined using the unpaired two-tailed Student's t-test. For comparison between two groups with a no normal distribution, two-tailed Mann-Whitney nonparametric test was used. For comparison of more than two groups, one-way or twoway ANOVA with Bonferroni post-hoc test was used. For Fig. 3c , Cox mixed model was applied when comparing tumour incidence of two groups, keeping the information about the experimental groups. We used the coxme function of the R package with the same name, to the cohort between day 0 and day 17, where two parabiont groups reach 50% of incidence. A P value o0.05 was considered significant.
Data availability. The authors declare that the data supporting the findings of this study are available within the article and its Supplementary Information files, or available from the authors on request.
